ACOUSTITECH · GLOBAL STRATEGY

Five Speakers.
One Clear Story.

12页英文答辩PPT双语演讲稿。按 1–3、4–6、7–8、9–10、11–12 分工，正常语速控制在10分钟以内。

English + 中文对照 Target: 8:40–9:20 Simple spoken English Updated: 2026-08-08
10:00
Speaker 1Slides 1–3 · 1:40
Speaker 2Slides 4–6 · 2:00
Speaker 3Slides 7–8 · 1:50
Speaker 4Slides 9–10 · 1:40
Speaker 5Slides 11–12 · 1:30
1

Opening, Recommendation & Threat

Slides 1–3

1:40

English script

Good morning. We are here as AcoustiTech's external strategy team. The company has built its position through strong acoustic technology and trusted professional relationships. But HearWell is about to launch a new product, and the market is changing fast because of AI, software, and the new OTC category.

Our core judgment is simple: the risk of standing still is now greater than the risk of controlled cannibalization.

We recommend three connected moves. First, keep the prescription flagship for complex and severe needs, while launching a separate OTC product family for mild-to-moderate users. Second, put both product lines on one shared AI, cloud, app, and clinical-evidence platform. Third, create a professional service bridge, so users can buy expert support separately when they need it.

HearWell's real threat is not only its lower price. Price and channel can be matched. The harder problem is its operating speed. Software can improve every week, user data can improve the algorithm, and a future-facing story can attract strong talent. At the same time, HearWell is expanding the whole market by reducing cost, stigma, and access barriers.

So the next question is: where should AcoustiTech compete, and what advantages can it still use? I will hand over to our second speaker.

中文对照

大家早上好。我们是 AcoustiTech 的外部战略顾问团队。公司过去依靠强大的声学技术和可信赖的专业关系建立了自己的市场地位。但 HearWell 即将发布新产品，而 AI、软件和新的 OTC 品类正在快速改变市场。

我们的核心判断很简单：现在，停滞不前的风险已经大于可控的自我蚕食风险。

我们建议采取三个相互关联的行动：保留处方旗舰产品，同时推出 OTC 产品系列；让两条产品线共享 AI、云平台、App 和临床证据平台；建立专业服务桥梁，让用户可以单独购买专家支持。

HearWell 真正的威胁不仅是价格更低，而是更快的运营速度。软件可以每周更新，用户数据可以持续改进算法，面向未来的企业叙事也更容易吸引优秀人才。同时，它还在降低价格、污名和购买门槛，扩大整个市场。

因此，下一个问题是：AcoustiTech 应该在哪里竞争，它还能利用哪些优势？下面交给第二位同学。

2

Market, Competitive Shift & VRIO

Slides 4–6

2:00

English script

Let us start with the market. There is still a large gap between low-cost OTC products and traditional prescription products. HearWell is not selling at the very bottom. Its price suggests that it is selling perceived value, not just cheap hardware. At the same time, only a minority of people with hearing loss use hearing aids today. This means demand is underserved, not absent.

AcoustiTech should therefore enter the open middle: more accessible than the traditional prescription offer, but more trusted than a low-cost consumer device.

The basis of competition is also changing. For the past forty years, the winner was the company with the best acoustic craft. Over the next two years, the winner will integrate hardware and software fastest. Over five years, the strongest position will come from useful data and credible clinical evidence.

This is important because AcoustiTech's assets are not obsolete; they are simply not being used in the right way. Its acoustic know-how, professional network, and complex-case experience remain valuable. The largest unused asset is its clinical and fitting data.

However, the company lacks AI talent, embedded software, cloud infrastructure, and direct-to-consumer capability. Our approach is: buy mature AI capability to save time, build the data and software backbone internally, and bond with professional partners to create remote fitting and follow-up services. AcoustiTech may buy technology, but it must keep control of clinical standards, data rights, and product architecture.

With that capability base clear, our third speaker will explain how the new business model should work.

中文对照

我们先看市场。低价 OTC 产品与传统处方产品之间仍然存在很大的价格空白。HearWell 并没有选择最低价格，这说明它销售的是消费者感知到的价值，而不仅仅是廉价硬件。同时，目前只有少部分听损人群在使用助听器，这说明需求没有消失，而是长期没有得到满足。

因此，AcoustiTech 应该进入中间空白：比传统处方产品更容易负担，同时比低价消费电子设备更值得信任。

竞争基础也在变化。过去胜负主要取决于声学工艺；未来两年取决于软硬件整合速度；未来五年，最强的竞争地位将来自有用的数据和可信的临床证据。

AcoustiTech 的资产并没有过时，只是没有被正确使用。声学技术、专业网络和复杂病例经验仍然有价值，而最大的闲置资产是临床与验配数据。

公司缺少 AI 人才、嵌入式软件、云基础设施和 DTC 能力。我们的思路是购买成熟 AI 能力来节省时间，在内部建设数据和软件底座，并与专业伙伴合作建立远程验配和随访服务。公司可以购买技术，但必须掌握临床标准、数据权利和产品架构。

明确这些能力基础之后，第三位同学将介绍新的业务模式如何运行。

3

Operating Model & Two-Year Roadmap

Slides 7–8

1:50

English script

Our operating model has two product tracks, one shared platform, and one service bridge.

The prescription flagship continues to serve complex and severe cases. It keeps full diagnosis, professional fitting, and real-ear verification. The OTC product family serves adults with perceived mild-to-moderate hearing loss. It offers self-fitting, clear pricing, remote-first support, and red-flag screening.

Between the two tracks, users can choose paid professional support, such as a remote consultation or a one-time in-person adjustment. This is not a third hardware product. It is a flexible service layer that helps users move to the right level of care.

Underneath, both tracks share the same acoustic platform, AI engine, account system, app, cloud infrastructure, data governance, quality system, and clinical-evidence process. Sharing the platform avoids duplicate investment and allows learning from both product lines.

The two-year plan is stage-gated. In the first three months, AcoustiTech forms a war room, contacts professional partners, and selects AI options. It then runs a limited regional pilot. From months ten to eighteen, the company validates the product, service model, and clinical evidence. National expansion only happens if return rate, gross margin, customer-acquisition cost, and customer satisfaction all pass the gate.

This two-year plan creates the evidence needed for a larger five-year transformation. Our fourth speaker will explain that direction.

中文对照

我们的运营模式包括两条产品线、一个共享平台和一座服务桥梁。

处方旗舰产品继续服务复杂和重度病例，保留完整诊断、专业验配和真耳测量。OTC 产品系列服务于自我感知为轻中度听损的成年人，提供自助验配、透明价格、远程支持和红旗症状筛查。

在两条产品线之间，用户可以选择付费专业支持。这不是第三种硬件产品，而是一个帮助用户进入合适服务等级的灵活服务层。

两条产品线共享声学平台、AI 引擎、账户系统、App、云基础设施、数据治理、质量体系和临床证据流程，以避免重复投资，并让两条产品线共同促进学习。

两年计划采用阶段闸门管理：前三个月建立战情室、联系伙伴并选择 AI 方案；随后开展有限区域试点；第十至十八个月验证产品、服务和临床证据。只有退货率、毛利率、获客成本和客户满意度全部达标，才进入全国扩张。

两年计划将为更大的五年转型积累证据。下面由第四位同学介绍长期方向。

4

Five-Year Direction & ENT Commitment

Slides 9–10

1:40

English script

The five-year goal is not simply to sell more hearing aids. It is to change the nature of the business.

Today, AcoustiTech mainly earns money from a one-time device sale. By year three, remote adjustment, software updates, and follow-up services can create an ongoing subscription relationship. By year five, the company may become a hearing-health platform serving consumers, insurers, and employers. But this expansion should happen only after the company proves real outcomes. The prescription business is the entry ticket because it provides clinical-grade data, professional trust, and regulatory capability.

This five-year vision is attractive, but it is only credible if AcoustiTech keeps the professional community on its side.

That is why the commitment to ENT specialists must be concrete and measurable. Experts should help define clinical endpoints and safety boundaries. They should join multicenter trials and review real-world outcomes. Professional services should be paid independently at fair-market value, never based on sales or referral volume. Red flags and complex cases should be routed to experts, and AcoustiTech should publish transparent safety and outcome reports.

The message is simple: AI should connect people to professional care earlier, not bypass professional diagnosis.

This trust commitment also defines how we manage risk. I will now hand over to our final speaker.

中文对照

五年目标不只是销售更多助听器，而是改变公司的业务性质。

今天，收入主要来自一次性设备销售；到第三年，远程调节、软件更新和随访服务可以建立持续订阅关系；到第五年，公司可能发展成服务消费者、保险公司和雇主的听力健康平台。但只有在证明真实效果之后才应扩张。处方业务是平台的入场券，因为它提供临床级数据、专业信任和监管能力。

这个五年愿景很有吸引力，但只有专业群体继续支持公司，它才具有可信度。

因此，对 ENT 专家的承诺必须具体并且可衡量。专家应参与定义临床终点和安全边界、加入多中心试验并审查真实世界结果。专业服务应按公允市场价格独立付费，不能与销量或转诊数量挂钩。红旗症状和复杂病例必须转交专家，公司还应公开安全与效果报告。

核心信息是：AI 应让需要帮助的人更早连接到专业服务，而不是绕过专业诊断。

这项信任承诺也决定了我们如何管理风险。下面交给最后一位同学。

5

Risk Control & Decision Request

Slides 11–12

1:30

English script

We divide the major risks into two groups.

The first group is irreversible. If AcoustiTech loses professional trust, creates a patient-safety problem, or violates medical and payment rules, the damage may be permanent. For these risks, the company should have zero tolerance: pause the OTC plan, delay the launch, or redesign the model immediately.

The second group is manageable. Cannibalization may be higher than expected, key AI talent may leave, or HearWell's new product may be clearly better. These risks should be controlled through predefined gates, limited investment, retention plans, and technology-partnership options.

We are therefore asking the board to approve five things: the dual-track product direction, the shared Digital Hearing Platform, a ninety-day expert coalition and pilot, a capped two-year investment envelope, and clear Scale, Pivot, or Stop authority at every gate.

HearWell will launch in two weeks, so AcoustiTech's response must begin now. But acting now does not mean making an unlimited commitment.

Our final recommendation is: protect trust, build speed, and let evidence earn the next dollar. Thank you.

中文对照

我们把主要风险分成两组。

第一组是不可逆风险。如果公司失去专业信任、造成患者安全问题，或者违反医疗与支付合规规则，损害可能是永久性的。对此应采取零容忍原则：暂停 OTC 计划、推迟发布，或立即重新设计模式。

第二组是可管理风险。自我蚕食可能超过预期，关键 AI 人才可能离职，或者 HearWell 的新产品可能明显更好。对此应通过预设闸门、有限投资、人才保留计划和技术合作选项进行控制。

我们请求董事会批准五项内容：双轨产品方向、共享数字听力平台、九十天专家联合体与试点、设有上限的两年投资预算，以及每个阶段明确的 Scale、Pivot 或 Stop 决策权。

HearWell 将在两周后发布产品，因此公司必须现在行动。但现在行动，并不意味着作出没有上限的承诺。

我们的最终建议是：守住信任，建立速度，让证据赢得下一笔投入。谢谢大家。

Rehearsal notes · 排练提醒

  1. 交接时不要重新介绍自己，只说稿件中的最后一句。
  2. 不要朗读页面上的所有标签，优先讲清每页最大标题背后的判断。
  3. 第2位强调竞争基础从 acoustic craft 转向 data and evidence。
  4. 第3位强调 service bridge 不是第三种硬件。
  5. 第4位必须把五年平台愿景与专业信任直接连接。
  6. 第5位在五项批准请求和最后一句话处适当放慢。
CASE COMPETITION · FACULTY Q&A

10 Questions an MBA Professor Is Most Likely to Ask

结合案例原始问题与 Case Competition Framework 设计。点击问题展开中英文建议回答。英文回答适合现场口头表达；财务数字为可缩放的管理情景，并非案例事实。

01What is the real strategic problem—not just the visible symptom?真正的战略问题是什么，而不仅仅是表面现象？

Suggested English answer

The visible symptom is HearWell's lower price. The real problem is a change in the basis of competition. The industry is moving from hardware cycles and professional distribution toward software updates, user data, AI learning, and direct access. AcoustiTech's strongest assets were built for the old model, while several critical capabilities for the new model are missing.

So our recommendation does not simply cut price. It protects the assets that remain hard to copy—clinical trust, complex-case expertise, and evidence—while adding the speed and access required by the new market.

中文对照

表面现象是 HearWell 的价格更低，真正的问题是竞争基础发生了变化。行业正在从硬件周期和专业分销，转向软件更新、用户数据、AI 学习和直接触达消费者。AcoustiTech 最强的资产服务于旧模式，而新模式所需的多项关键能力仍然缺失。

因此，我们的建议不是简单降价，而是在增加速度和市场触达能力的同时，保护临床信任、复杂病例经验和临床证据这些仍然难以复制的资产。

02What do SWOT, PEST, and Porter's Five Forces tell you?SWOT、PEST 和波特五力分别得出了什么结论？

Suggested English answer

PEST: regulation has opened the OTC category; technology is shortening product cycles; social stigma is falling; and economic pressure makes traditional prices harder to defend.

Five Forces: entry barriers are lower in OTC, buyer power and substitutes are rising, and rivalry is shifting toward software and customer access. Supplier power also increases where AcoustiTech depends on scarce AI talent or external platforms.

SWOT: the company has trust, acoustic know-how, clinical capability, and complex-case expertise. It lacks AI, cloud, DTC, and low-cost operating capabilities. The opportunity is a larger underserved market; the threat is losing learning speed, talent, and channel support. Together, the frameworks support a controlled dual-track response rather than pure defense.

中文对照

PEST：监管开放了 OTC 品类；技术缩短了产品迭代周期；社会污名正在下降；经济压力让传统高价越来越难维持。

波特五力：OTC 降低了进入壁垒，提高了买方力量和替代威胁，竞争焦点转向软件和消费者触达。在稀缺 AI 人才及外部平台方面，供应商力量也会上升。

SWOT：优势是专业信任、声学技术、临床能力和复杂病例经验；弱点是 AI、云、DTC 和低成本运营能力；机会是更大的未服务市场；威胁是失去学习速度、人才和渠道支持。因此，三个框架共同支持有控制的双轨转型，而不是单纯防守。

03What alternatives did you consider, and why is dual-track better?你们考虑了哪些备选方案？为什么双轨方案更优？

Suggested English answer

We considered four options: defend the premium prescription business only; launch a low-price OTC product under the main model; acquire or license the full solution; or build a dual-track model on one shared platform.

We compared them on five criteria: speed, protection of clinical trust, access to new users, capital exposure, and long-term learning. Premium-only defense protects margin but loses the growth market and data. A full OTC shift moves faster but creates channel conflict and brand dilution. A full acquisition is fast but expensive and may transfer too much control. Dual-track scores best overall because it separates customer promises at the front end while sharing expensive capabilities at the back end.

中文对照

我们考虑了四个方案：只防守高端处方业务；在现有模式下推出低价 OTC 产品；整体收购或授权完整解决方案；以及在共享平台上建设双轨模式。

评价标准包括速度、临床信任保护、新用户覆盖、资本风险和长期学习。只守处方业务可以保护利润，但会失去增长市场和数据；全面转向 OTC 虽然快，却会带来渠道冲突和品牌稀释；整体收购速度快但成本高，也可能失去控制权。双轨方案综合表现最好，因为它在前台区分客户承诺，在后台共享高成本能力。

04Which current resource is most valuable, and which new capability is most urgent?现有资源中哪一项最有价值？最紧急的新能力是什么？

Suggested English answer

The most valuable underused resource is the combination of clinical history, fitting data, professional trust, and complex-case expertise. Data alone is not automatically a moat. It becomes valuable when it is authorized, labeled with outcomes, governed properly, and linked to clinical evidence.

The most urgent capability is not simply “AI.” It is the ability to run a fast, safe learning system: embedded software, over-the-air updates, cloud data governance, product analytics, clinical validation, and rapid decision-making. Without that system, buying an algorithm will not change the company's operating speed.

中文对照

最有价值但尚未充分利用的资源，是临床历史、验配数据、专业信任和复杂病例经验的组合。数据本身不会自动形成护城河，只有经过用户授权、具备效果标签、得到合规治理并与临床证据连接时，才真正有价值。

最紧急的新能力也不只是“拥有 AI”，而是运行一套快速且安全的学习系统，包括嵌入式软件、空中升级、云端数据治理、产品分析、临床验证和快速决策。没有这套系统，即使买到算法，也无法改变公司的运营速度。

05Why buy AI capability instead of building it internally?为什么 AI 能力应该购买，而不是完全内部自建？

Suggested English answer

Because the immediate constraint is time, not only money. HearWell launches in two weeks, while an internal AI team and a working learning platform could take years to mature. AcoustiTech should selectively buy or license mature algorithms, specialist talent, or a small team to shorten the first learning cycle.

However, we are not recommending outsourcing the strategy. AcoustiTech must build and own the shared architecture, data rights, clinical standards, safety controls, and product roadmap. In short: buy speed, build control, and partner for reach.

中文对照

因为眼前最紧缺的是时间，而不只是资金。HearWell 两周后就要发布产品，而内部 AI 团队和完整学习平台可能需要多年才能成熟。因此，AcoustiTech 应有选择地购买或授权成熟算法、专业人才或小型团队，以缩短第一个学习周期。

但这不等于外包战略。公司必须自己建设并掌握共享架构、数据权利、临床标准、安全控制和产品路线图。简单说就是：购买速度，内部建立控制，与伙伴合作获得触达能力。

06How will you prevent channel conflict and keep the CEO's promise to ENT specialists?如何避免渠道冲突，并兑现 CEO 对 ENT 专家的承诺？

Suggested English answer

We separate products, prices, service rights, customer-support queues, sales incentives, and P&L, even though the technology platform is shared. The prescription flagship remains the clear path for complex and severe cases. OTC uses red-flag screening and a paid professional service bridge rather than pretending every user can self-manage.

The promise becomes measurable through an expert advisory group, shared clinical endpoints, multicenter validation, fair-market payment for independent services, priority access to professional tools, and an annual transparency report. No payment should depend on product sales or referral volume.

中文对照

虽然技术平台共享，但产品、价格、服务权益、客服队列、销售激励和损益必须隔离。复杂和重度病例继续明确进入处方旗舰路径；OTC 设置红旗症状筛查和付费专业服务桥梁，而不是假设所有用户都能自助处理。

CEO 的承诺通过专家顾问组、共同制定临床终点、多中心验证、按公允市场价格支付独立服务、优先开放专业工具和年度透明度报告来兑现。任何报酬都不能与产品销量或转诊数量挂钩。

07What makes your two-year implementation plan SMART?你们的两年实施计划如何满足 SMART 原则？

Suggested English answer

It is specific and time-bound because each stage has a clear owner, output, date, and gate. Within 90 days, AcoustiTech should form the war room and expert coalition, select the AI path, and establish financial and product baselines. By month nine, it should complete a limited regional pilot. By month eighteen, the product, service model, and clinical program must pass four gates: return rate, gross margin, customer-acquisition economics, and customer satisfaction. By month twenty-four, expansion remains conditional on channel retention and safety performance.

Because the case lacks operating baselines, exact thresholds must be calibrated with company data in the first 30 days. A metric without a verified baseline is not truly measurable.

中文对照

它具备明确性和时间约束，因为每个阶段都有负责人、交付物、日期和闸门。九十天内建立战情室和专家联合体，确定 AI 路径，并建立财务与产品基线；第九个月前完成有限区域试点；第十八个月前让产品、服务模式和临床计划通过退货率、毛利率、获客经济性和客户满意度四道闸门；第二十四个月是否扩张，仍取决于渠道留存和安全表现。

由于案例缺少经营基线，具体阈值必须在最初三十天内用公司真实数据校准。没有经过验证的基线，指标就不能真正做到可衡量。

08Why is the five-year hearing-health platform credible rather than wishful thinking?为什么五年听力健康平台不是空想？

Suggested English answer

It is a direction, not an unconditional forecast. The sequence matters. First, AcoustiTech proves that software and remote support improve hearing outcomes. Second, it creates a recurring relationship through adjustment, monitoring, and follow-up. Only after those results are verified should it approach insurers or employers.

The platform thesis is credible because AcoustiTech already has the professional access and clinical capability needed to collect higher-quality outcome evidence. It becomes wishful thinking if the company expands into broad health data before proving hearing outcomes, user consent, privacy governance, and sustainable unit economics.

中文对照

它是一项方向，而不是无条件预测，关键在于顺序。第一步证明软件和远程支持能够改善听力效果；第二步通过调节、监测和随访建立持续关系；只有这些结果得到验证之后，才面向保险公司或雇主扩张。

这一平台逻辑之所以可信，是因为 AcoustiTech 已经拥有专业触达和临床能力，可以积累质量更高的效果证据。如果在证明听力效果、用户授权、隐私治理和可持续单位经济之前，就扩张到广泛健康数据，它就会变成空想。

09What are the financial return and investment limits?投资上限、财务回报和 ROI 分别是多少？

Suggested English answer

Because the case provides no full financial statements, we use a scalable scenario rather than claiming false precision. If current annual revenue is 100 million dollars, the proposed 24-month capital cap is 5.5 million, or 5.5% of revenue. The first 90-day release is only 0.4 million. Total five-year investment is 7 million.

In the base scenario, five-year attributable benefit is 11.5 million: 8 million from protecting the prescription core, 2 million from OTC and services, and 1.5 million from operating efficiency. Net benefit is 4.5 million, ROI is 64%, and payback occurs around year four.

The board should not approve all seven million upfront. Funding is released only if cash-flow coverage is at least three times, prescription contribution remains at least 95% of baseline, two OTC cohorts show non-negative contribution after returns and support, and no major clinical or compliance event occurs.

Assumption: all figures scale from a $100M revenue base and must be recalibrated with company data within 30 days.

中文对照

由于案例没有完整财务报表，我们使用可缩放的情景模型，而不是制造虚假的精确度。假设当前年收入为一亿美元，两年资本上限为五百五十万美元，即收入的 5.5%；最初九十天只释放四十万美元；五年总投资为七百万美元。

在基准情景下，五年可归因收益为一千一百五十万美元：八百万来自保护处方核心业务，两百万来自 OTC 与服务，一百五十万来自运营效率。净收益为四百五十万美元，ROI 为 64%，约在第四年回收。

董事会不应一次批准全部七百万。只有现金流覆盖至少三倍、处方贡献不低于基线的 95%、连续两个 OTC cohort 在退货和服务成本后贡献不为负，并且没有重大临床或合规事件时，才继续释放资金。

假设说明：所有数字均以一亿美元收入为缩放基准，必须在三十天内用公司真实数据重新校准。
10What would make you stop, pivot, or change the recommendation?出现什么情况时，你们会停止、转向或修改建议？

Suggested English answer

We stop immediately for irreversible risks: a failed clinical endpoint, a serious safety event, a regulatory challenge, or a payment design that creates compliance risk. We pause OTC expansion if professional-partner loss exceeds the agreed limit or if prescription contribution falls materially below the baseline.

We pivot if users need more support than expected, customer acquisition and returns make OTC contribution unattractive, or HearWell is clearly ahead after the launch review. Possible pivots include a smaller regional model, a service-led offer, licensing external technology, or defending the complex-care niche.

The recommendation is therefore not “launch OTC at any cost.” It is “run a controlled learning strategy with predefined exit conditions.”

中文对照

如果出现不可逆风险，我们立即停止：临床终点未达标、严重安全事件、监管质询，或者支付设计产生合规风险。如果专业伙伴流失超过约定上限，或处方业务贡献明显低于基线，就暂停 OTC 扩张。

如果用户需要的支持明显高于预期、获客和退货导致 OTC 贡献缺乏吸引力，或者发布会后确认 HearWell 明显领先，则进行转向。备选方向包括缩小到区域模式、改为服务主导、授权外部技术，或集中防守复杂病例细分市场。

因此，我们的建议不是“不惜代价推出 OTC”，而是“用预设退出条件运行一项可控的学习战略”。